NVAX · Novavax Inc · Proposed Sales
$7.91
-0.06 (-0.69%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$1.31B
Shares
165.01M
Volume · Nov 19
1.15M
Avg daily vol (3M)
6.86M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2025-05-19 | YOUNG JAMES F | Former Director | 10,000 | 2025-05-19 | Merrill Lynch |
| 2025-04-14 | YOUNG JAMES F | Former Director | 4,000 | 2025-04-14 | Merrill Lynch |
| 2024-12-26 | YOUNG JAMES F | Director | 10,000 | 2024-12-24 | Merrill Lynch |
| 2024-12-13 | Rachel K. King | Board Member | 4,150 | 2024-12-13 | UBS Financial Services Inc |
| 2024-09-18 | Dubovsky Filip | Officer | 7,335 | 2024-09-18 | Merrill Lynch |
| 2024-06-18 | YOUNG JAMES F | Director | 15,000 | 2024-06-18 | Merrill Lynch |
| 2024-06-17 | Dubovsky Filip | Officer | 13,904 | 2024-06-17 | Merrill Lynch |
| 2024-05-14 | Dubovsky Filip | Officer | 47,312 | 2024-05-14 | Merrill Lynch |
Showing 1–8 of 8 filings
Key facts
CIK
1000694
CUSIP
670002401
13F (30d)
290 filings
249 filers
Visit website
Investor relations